Phage Therapy

Overview

Phage therapy uses bacteriophages — viruses that infect and lyse specific bacteria — as precision antimicrobials. Unlike broad-spectrum antibiotics, phages target specific bacterial species or strains, sparing the commensal microbiome. In the WikiBiome framework, phage therapy represents a targeted ecological intervention (Karen's Brain Primitive 5) — suppressing specific pathobionts without collateral dysbiosis.

Advantages Over Antibiotics

  • Species-specific: Each phage infects a narrow host range, preserving the broader microbiome.
  • Biofilm penetration: Phages encode depolymerases that degrade biofilm extracellular matrix — addressing the biofilm resistance problem that defeats antibiotics.
  • Self-amplifying: Phages replicate at the site of infection, increasing in number where the target pathogen is most abundant.
  • Co-evolution capacity: Phage-resistant bacterial mutants often lose virulence factors, creating a fitness trade-off.

Clinical Evidence

  • Chronic prostatitis: Phage endolysins tested against biofilm-forming bacteria in chronic pelvic pain syndrome [1].
  • E. coli prostatitis case report: Phage therapy cleared dominant E. coli biofilm, unmasking co-infecting Serratia marcescens — demonstrating polymicrobial complexity [2].
  • Safety/efficacy systematic review: Phage therapy is generally safe with favorable outcomes in compassionate-use settings, though RCT evidence remains limited [3].
  • CRC virome: Altered bacteriophage communities in CRC, with phage-bacteria dynamics influencing tumor progression [4].
  • Phage nanovectors: Engineered phage (M13) as drug delivery vehicles for photodynamic CRC therapy [5].

Phage Cocktails

Phage cocktails combine multiple phages targeting the same species (different receptors) or different species in a polymicrobial infection. The cocktail approach:

  • Reduces emergence of phage-resistant mutants.
  • Broadens the host range within a target species.
  • Can address polymicrobial biofilms when combined with functional shielding-disrupting antifungals.

Metal Connection

Phage therapy intersects with metallomics in two ways:

  1. Some phage endolysins are zinc-dependent metalloenzymes — zinc availability affects lytic activity.
  2. Phage therapy can replace antibiotics in scenarios where metal-antibiotic co-selection (co selection) drives AMR — phages exert no metal-resistance selection pressure.

Cross-References

References (6)

  1. Roy H. Stevens, Hongming Zhang, Michal Kajsik et al. (2023). Stevens 2023 — Successful Use of a Phage Endolysin for Treatment of CPPS/Chronic Bacterial Prostatitis. Frontiers in Medicine. doi:10.3389/fmed.2023.1238147
  2. Apurva Virmani Johri, Pranav Johri, Naomi Hoyle et al. (2023). Johri 2023 — Successful Treatment of Recurrent E. coli Infection with Bacteriophage Therapy for Chronic Bacterial Prostatitis. Frontiers in Pharmacology. doi:10.3389/fphar.2023.1243824
  3. Saartje Uyttebroek, Baisong Chen, Jolien Onsea et al. (2022). Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. The Lancet Infectious Diseases. doi:10.1016/S1473-3099(21)00612-5
  4. Si Xian Ho, Jia-Hao Law, Chin-Wen Png et al. (2024). Alterations in colorectal cancer virome and its persistence after surgery. Scientific Reports. doi:10.1038/s41598-024-53041-z
  5. Eleonora Turrini, Luca Ulfo, Paolo Emidio Costantini et al. (2024). Molecular engineering of a spheroid-penetrating phage nanovector for photodynamic treatment of colon cancer cells. Cellular and Molecular Life Sciences. doi:10.1007/s00018-024-05174-7
  6. Zheng S, Chen H, Yang H et al. (2024). Zheng 2024 — Differential enrichment of bacteria and phages in vaginal microbiomes in PCOS and obesity: shotgun sequencing analysis. Frontiers in Microbiomes. doi:10.3389/frmbi.2023.1229723

Related Articles